Trials / Completed
CompletedNCT00856206
Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)
A Multi-Center, Randomized, Double-Blind, Placebo Controlled Trial of the Safety of Rilonacept for the Prophylaxis of Gout Flares in Patients on Urate- Lowering Therapy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,315 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this clinical research study is to determine the safety and effectiveness of an experimental drug called rilonacept in subjects with gout who are on urate-lowering therapy. Subjects will participate in this study for approximately 20 weeks. Rilonacept is being studied for use in preventing gout flares in subjects on urate-lowering therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Rilonacept | Rilonacept 160 mg subcutaneous injection once a week |
| OTHER | Placebo | Placebo subcutaneous injection once a week |
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2011-01-01
- Completion
- 2011-01-01
- First posted
- 2009-03-05
- Last updated
- 2017-04-28
- Results posted
- 2017-04-28
Locations
124 sites across 6 countries: United States, Germany, India, Indonesia, South Africa, Taiwan
Source: ClinicalTrials.gov record NCT00856206. Inclusion in this directory is not an endorsement.